Your browser doesn't support javascript.
loading
Clinical Subgroups in Bilateral Meniere Disease.
Frejo, Lidia; Soto-Varela, Andres; Santos-Perez, Sofía; Aran, Ismael; Batuecas-Caletrio, Angel; Perez-Guillen, Vanesa; Perez-Garrigues, Herminio; Fraile, Jesus; Martin-Sanz, Eduardo; Tapia, Maria C; Trinidad, Gabriel; García-Arumi, Ana María; González-Aguado, Rocío; Espinosa-Sanchez, Juan M; Marques, Pedro; Perez, Paz; Benitez, Jesus; Lopez-Escamez, Jose A.
Afiliação
  • Frejo L; Otology and Neurotology Group CTS495, Department of Genomic Medicine - Centro de Genómica e Investigación Oncológica - Pfizer/Universidad de Granada/Junta de Andalucía (GENYO) , Granada , Spain.
  • Soto-Varela A; Department of Otorhinolaryngology, Division of Otoneurology, Complexo Hospitalario Universitario , Santiago de Compostela , Spain.
  • Santos-Perez S; Department of Otorhinolaryngology, Division of Otoneurology, Complexo Hospitalario Universitario , Santiago de Compostela , Spain.
  • Aran I; Department of Otolaryngology, Complexo Hospitalario de Pontevedra , Pontevedra , Spain.
  • Batuecas-Caletrio A; Department of Otolaryngology, Hospital Universitario Salamanca , Salamanca , Spain.
  • Perez-Guillen V; Department of Otorhinolaryngology, Hospital Universitario La Fe , Valencia , Spain.
  • Perez-Garrigues H; Department of Otorhinolaryngology, Hospital Universitario La Fe , Valencia , Spain.
  • Fraile J; Department of Otolaryngology, Hospital Miguel Servet , Zaragoza , Spain.
  • Martin-Sanz E; Department of Otolaryngology, Hospital Universitario de Getafe , Getafe , Spain.
  • Tapia MC; Department of Otorhinolaryngology, Instituto Antolí Candela , Madrid , Spain.
  • Trinidad G; Department of Otorhinolaryngology, Division of Otoneurology, Complejo Hospitalario Badajoz , Badajoz , Spain.
  • García-Arumi AM; Department of Otorhinolaryngology, Hospital Universitario Vall d'Hebron , Barcelona , Spain.
  • González-Aguado R; Department of Otorhinolaryngology, Hospital Universitario Marqués de Valdecilla , Santander, Cantabria , Spain.
  • Espinosa-Sanchez JM; Otology and Neurotology Group CTS495, Department of Genomic Medicine - Centro de Genómica e Investigación Oncológica - Pfizer/Universidad de Granada/Junta de Andalucía (GENYO), Granada, Spain; Department of Otorhinolaryngology, Hospital San Agustin, Linares, Jaen, Spain.
  • Marques P; Department of Otorhinolaryngology, Centro Hospitalar de São João, EPE, University of Porto Medical School , Porto , Portugal.
  • Perez P; Department of Otorhinolaryngology, Hospital Cabueñes , Gijón , Spain.
  • Benitez J; Department of Otolaryngology, Hospital Universitario de Gran Canaria Dr. Negrin , Las Palmas , Spain.
  • Lopez-Escamez JA; Otology and Neurotology Group CTS495, Department of Genomic Medicine - Centro de Genómica e Investigación Oncológica - Pfizer/Universidad de Granada/Junta de Andalucía (GENYO), Granada, Spain; Department of Otolaryngology, Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitalario Un
Front Neurol ; 7: 182, 2016.
Article em En | MEDLINE | ID: mdl-27822199
ABSTRACT
Meniere disease (MD) is a heterogeneous clinical condition characterized by sensorineural hearing loss, episodic vestibular symptoms, and tinnitus associated with several comorbidities, such as migraine or autoimmune disorders (AD). The frequency of bilateral involvement may range from 5 to 50%, and it depends on the duration of the disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD (BMD) to identify the best predictors to define clinical subgroups with a potential different etiology to improve the phenotyping of BMD and to develop new treatments. We have defined five clinical variants in BMD. Group 1 is the most frequently found, includes 46% of patients, and is defined by metachronic hearing loss without migraine and without AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, while group 4, that includes 12% of patients, is associated by the presence of migraine in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach can be helpful in selecting patients for genetic and clinical research. However, further studies will be required to improve the phenotyping in these clinical variants for a better understanding of the diverse etiological factors contributing to BMD.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Neurol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Neurol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Espanha